Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orexo ABORXOY 35 3-Year Book Growth Rate is 35.80% as of Jun. 2026, which is 953% above its 10-year median of 3.40. GuruFocus rates ORXOY with a GF Score™ of 35/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 912 Drug Manufacturers companies, Orexo AB ranks better than 93.2% on this metric.
During the past 3 years, the average Book Value per Share Growth Rate was 35.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Orexo AB was 136.80% per year. The lowest was -52.80% per year. And the median was 3.40% per year.
Orexo AB (OTCPK:ORXOY) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Orexo AB 3-Year Book Growth Rate Related Terms
ORXOY vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Orexo AB's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 35.80% mean?
Orexo AB (ORXOY) has a 3-Year Book Growth Rate of 35.80% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Orexo AB and its competitors. This is 953% above median its historical median of 3.40. According to the industry distribution chart, Orexo AB ranks #62 out of 912 companies in the Drug Manufacturers industry, placing it in the top 6.8%.
Is Orexo AB's 3-Year Book Growth Rate too high?
Orexo AB's current 3-Year Book Growth Rate of 35.80% is 953% above median its 10-year median of 3.40. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Orexo AB's value of 35.80% is 678.3% above this industry median. Based on the distribution chart, Orexo AB ranks #62 out of 912 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orexo AB has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #62 out of 912 companies for 3-Year Book Growth Rate. This places Orexo AB in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 4.60. Orexo AB's value of 35.80% is 678.3% above this benchmark. While the company's 10-year median is 3.40 vs. the industry median of 4.60, Orexo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current 3-Year Book Growth Rate of 35.80% is 678.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Orexo AB and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current 3-Year Book Growth Rate is 35.80%, which is 953% above median its own 10-year median of 3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOY) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $1.39 — trading 256.4% above its estimated fair value. The current 3-Year Book Growth Rate is 35.80%, which is 953% above median its 10-year median of 3.40 and 678.3% above the Drug Manufacturers industry median of 4.60. Orexo AB's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Orexo AB (ORXOY), the current 3-Year Book Growth Rate is 35.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOY) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $1.39 is trading 256.4% above its estimated GF Value™ of $0.39.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOY:
3-Year Book Growth Rate: 35.80% (953% above median its 10-year median of 3.40)
GF Value™: $0.39 vs. price of $1.39 (256.4% above fair value)
Industry Position: 678.3% above the Drug Manufacturers median (#62 of 912)
No single metric tells the full story. See the ORXOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
35GF Score
Get the complete analysis for ORXOY
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOY has been successfully added to your 
